Vor Biopharma Inc. — Q1 2022 Form 10-Q
Business context and reporting period. The filing covers the three months ended March 31, 2022. Vor is a clinical-stage cell and genome engineering company developing engineered hematopoietic stem cells and targeted therapies for blood cancers. It has no approved products and has not generated product revenue.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 or comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $15.3 million | $8.9 million |
| General and administrative expense | $7.5 million | $4.8 million |
| Total operating expenses | $22.8 million | $13.7 million |
| Net loss | $22.7 million | $13.7 million |
| Basic and diluted loss per share | $0.61 | $0.67 |
| Net cash used in operating activities | $22.9 million | $17.6 million |
| Cash, cash equivalents and marketable securities | $181.6 million | $207.5 million at December 31, 2021 |
There are no meaningful operating margins to assess because the company has no revenue. At March 31, 2022, current assets were $190.3 million and current liabilities were $18.1 million; total assets were $234.3 million. Vor reported no debt outstanding. It had $29.0 million of operating lease liabilities and an accumulated deficit of $152.9 million.
Material changes versus the prior comparable period
- Operating expenses increased $9.1 million year over year. R&D rose $6.3 million, mainly from higher external research and clinical-development costs, staffing and facilities; G&A increased $2.7 million, primarily from personnel, professional fees and facilities.
- Net loss increased $9.0 million, while loss per share narrowed to $0.61 from $0.67, reflecting a higher weighted-average share count following the 2021 IPO.
- Operating cash use increased $5.3 million. Investing cash use was $7.1 million, including $5.0 million of marketable-security purchases and $2.0 million of property and equipment purchases.
- Marketable securities had $1.1 million of unrealized losses, recorded in other comprehensive loss, attributed to rising interest rates; the company reported no credit losses.
- The first amendment to the Cambridge lease commenced for accounting purposes in January 2022, increasing recognized lease assets and liabilities. A second amendment, with approximately $21.9 million of fixed payments, had not yet commenced for accounting purposes.
Outlook, commentary and risks
- Management expected the March 31 cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into Q4 2023. The company cautioned that this estimate depends on assumptions and may prove inaccurate.
- Vor expects significant ongoing losses and expense growth and says it will need substantial additional funding. It filed a shelf registration statement for offerings up to $350 million and established an at-the-market facility to sell up to $125 million of common stock, which could dilute shareholders.
- VOR33 was in an actively recruiting Phase 1/2a trial with Mylotarg; initial clinical data were anticipated in the second half of 2022. COVID-19-related site activation and enrollment delays had occurred.
- VCAR33 AUTO was being studied in an NMDP-sponsored Phase 1/2 trial; initial data were expected in 2022, subject to the investigator’s timing. Vor planned to submit an IND for VCAR33 ALLO in the first half of 2023. The company planned to collect initial VOR33 and VCAR33 ALLO data before submitting an IND for the combined Treatment System.
- Key risks include unvalidated engineered-cell and genome-editing technology, clinical and regulatory uncertainty, potential serious adverse effects, manufacturing and third-party supply dependence, intellectual-property and licensing risks, competition, and the possibility that additional financing will not be available on acceptable terms.
- The Chief Medical Officer’s resignation was effective May 6, 2022; management said it was seeking a replacement. This occurred after quarter-end.
Important facts for investors to verify
- Whether trial enrollment, safety and data-release timelines for VOR33 and VCAR33 AUTO matched the expectations stated in this filing.
- Whether the stated cash runway remains valid given quarterly cash burn, planned clinical and manufacturing spending, and lease commitments.
- Whether the shelf or ATM facility has been used, and the resulting proceeds, share issuance and dilution.
- Progress on the VCAR33 ALLO IND plan and the data-dependent timing of the combined Treatment System.
- Any subsequent developments involving the Chief Medical Officer vacancy, COVID-related delays, or manufacturing and supply constraints.